---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-127352"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2023-12-19T23:59:59+00:00"
generated_at: "2026-06-07T10:20:07.013350+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools and SomaLogic update merger presentation; target $300M+ revenue, $80M synergies by 2026

## Summary
- All-stock merger: SLGC shareholders receive 1.1100 LAB shares per share; expected close Q1 2024.
- Pro-forma combined 2026E revenue >$300M and $80M run-rate cost synergies fully achieved by 2026.
- Combined cash at close >$500M; ownership: SLGC ~57%, LAB ~43% (incl. Series B preferred).
- Shareholder vote set for Jan 4, 2024; supportive voting agreements from ~16% of LAB and ~1% of SLGC shareholders.
- Presentation defends merger against Madryn allegations, citing premium, governance, and reduced execution risk.

## SEC filing metadata
- accession: 0001104659-23-127352
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2023-12-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000110465923127352/0001104659-23-127352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000110465923127352/tm2333207d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-127352
- JSON: https://secwatch.observer/filing/0001104659-23-127352.json
- Plain text: https://secwatch.observer/filing/0001104659-23-127352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.